Belite Bio (NASDAQ:BLTE – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Institutional & Insider Ownership 3.8% of Belite […]
Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) – Stock analysts at Wedbush reduced their Q2 2023 earnings per share estimates for shares of Foghorn Therapeutics in a report issued on Tuesday, May 9th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.74) per share for the quarter, down from their […]